The Merck KGAA reacts to media reports and confirms advanced talks with Springworks Therapeutics.
The Darmstadt also confirm that no legally binding agreement had been made. There is no certainty that a transaction will come about. In addition, critical conditions would still have to be met. Previously, Reuters had reported that the pharmaceutical and technology group had discussions about a possible takeover of the US Cancer Specialist Springworks Therapeutics.
The Merck share is at times 0.82 percent more at EUR 136.05 in Xetra trading. Meanwhile, the SpringWorks share in Nasdaq trading ultimately jumped by 34.06 percent high to $ 54.00. On Tuesday, a further 1.46 percent will be up to $ 54.79 on Tuesday.
Dow Jones
Selected leverage products on Merck
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we will show you suitable open-end products on Merck
The lever must be between 2 and 20
Advertising